Brtiannia Pharmaceuticals

Brtiannia Pharmaceuticals' main area of interest has always been the development of innovative, patient-centered technologies to effectively deliver treatments for patients with Parkinson's disease. It focuses on innovative products for chronic and severe diseases, as well as treatments for Parkinson's disease. Additionally, it collaborates with expert focus groups, funds clinical trials, and invests in care programs that optimize treatment plans and improve quality of life.